Key Highlights
- Abbas Kazimi appointed as CEO and Board Member of Nimbus Therapeutics, effective immediately.
- Succeeds Jeb Keiper, MS, MBA, following a planned leadership transition.
- Kazimi played a pivotal role in securing over $7 billion in deals, including the TYK2 sale to Takeda.
- Nimbus advances drug discovery with its computational platform, focusing on oncology and autoimmune diseases.
- Continued industry validation, including its WRN and SIK inhibitor programs and collaborations with Lilly.
Source: Business Wire
Notable Quotes
- “We are excited to announce the next chapter in leadership at Nimbus. The board is unanimous in its support of Abbas… With the recent appointment of Peter Tummino as President of R&D, we are confident Abbas will continue to deliver on the company’s mission to bring breakthrough medicines to patients.” — Bruce Booth, D. Phil., Chairman of the Board and Co-Founder at Nimbus Therapeutics
- “After spending over a decade at Nimbus, I couldn’t be more proud of the incredible team we’ve built… I can think of no better leader than Abbas, who has led this team in creating an incredibly valuable biotech company.” — Jeb Keiper, Former CEO at Nimbus Therapeutics
- “I am honored to lead Nimbus at this pivotal time in the company’s evolution. Our robust pipeline… continues to validate our approach and strengthen our position in the industry.” — Abbas Kazimi, CEO at Nimbus Therapeutics
Why This Matters
This leadership transition at Nimbus Therapeutics marks a significant milestone for the company, as it continues to leverage computational drug discovery to develop breakthrough small molecule medicines. Under Kazimi’s leadership, Nimbus is well-positioned to advance its oncology and autoimmune drug pipeline and further its impact in biotech through strategic industry collaborations.
